These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24318486)

  • 101. HIV-1 diversity after a class switch failure.
    Kolber MA; Buendia P; Degruttola V; Moore RD
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1175-80. PubMed ID: 20854203
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Predominance of CRF06_cpx and Transmitted HIV Resistance in Algeria: Update 2013-2014.
    Abdellaziz A; Papuchon J; Khaled S; Ouerdane D; Fleury H; Recordon-Pinson P
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):370-2. PubMed ID: 26529365
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.
    Yendewa GA; Lakoh S; Yendewa SA; Bangura K; Tabernilla A; Patiño L; Jiba DF; Vandy AO; Massaquoi SP; Osório NS; Deen GF; Sahr F; Salata RA; Poveda E
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573296
    [TBL] [Abstract][Full Text] [Related]  

  • 104. No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection.
    Abdi B; Nguyen T; Brouillet S; Desire N; Sayon S; Wirden M; Jary A; Achaz G; Assoumou L; Palich R; Simon A; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG; Soulie C
    AIDS; 2020 Oct; 34(12):1745-1753. PubMed ID: 32694418
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study.
    Costagliola D; Descamps D; Assoumou L; Morand-Joubert L; Marcelin AG; Brodard V; Delaugerre C; Mackiewicz V; Ruffault A; Izopet J; Plantier JC; Tamalet C; Yerly S; Saidi S; Brun-Vezinet F; Masquelier B;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):12-8. PubMed ID: 17514016
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays.
    Peeters M; Aghokeng AF; Delaporte E
    Clin Microbiol Infect; 2010 Oct; 16(10):1525-31. PubMed ID: 20649800
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.
    Hedskog C; Mild M; Jernberg J; Sherwood E; Bratt G; Leitner T; Lundeberg J; Andersson B; Albert J
    PLoS One; 2010 Jul; 5(7):e11345. PubMed ID: 20628644
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Moderate rate of transmitted resistance mutations to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin.
    Tchiakpe E; Keke RK; Vidal N; Ahoussinou C; Sekpe O; Dagba HG; Gbaguidi E; Tonoukouen C; Afangnihoun A; Bachabi M; Gangbo FA; Diop-Ndiaye H; Toure-Kane C
    BMC Res Notes; 2020 Jul; 13(1):314. PubMed ID: 32616057
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.
    Sigaloff KC; Ramatsebe T; Viana R; de Wit TF; Wallis CL; Stevens WS
    AIDS Res Hum Retroviruses; 2012 Feb; 28(2):171-5. PubMed ID: 21819219
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Determination of drug resistance and virus typology in HIV-1-positive pediatric patients in Istanbul, Turkey.
    Yoldaş O; Ağaçfidan A; Lübke N; Somer A; Hançerli S; Verheyen J; Kaiser R; Akgül B
    Intervirology; 2014; 57(5):297-9. PubMed ID: 24992950
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Deep Sequencing of HIV-1 in Cerebrospinal Fluid.
    Tong CY; Costelloe S; Hubb J; Mullen J; O'Shea S; Marta M; Kulasegaram R; Rackstraw S
    Clin Infect Dis; 2015 Sep; 61(6):1022-5. PubMed ID: 26021989
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Near-point-of-care assay with a visual readout for detection of HIV-1 drug resistance mutations: A proof-of-concept study.
    Gomez-Martinez J; Foulongne V; Laureillard D; Nagot N; Montès B; Cantaloube JF; Van de Perre P; Fournier-Wirth C; Molès JP; Brès JC
    Talanta; 2021 Aug; 231():122378. PubMed ID: 33965042
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory.
    Avidor B; Girshengorn S; Matus N; Talio H; Achsanov S; Zeldis I; Fratty IS; Katchman E; Brosh-Nissimov T; Hassin D; Alon D; Bentwich Z; Yust I; Amit S; Forer R; Vulih Shultsman I; Turner D
    J Clin Microbiol; 2013 Mar; 51(3):880-6. PubMed ID: 23284027
    [TBL] [Abstract][Full Text] [Related]  

  • 114. The emergence of an unassigned complex recombinant form in a Pakistani HIV-infected individual.
    Tariq U; Iftikhar A; Zahid D; Sultan F; Mahmood SF; Naeem S; Ali S; Abidi SH
    Arch Virol; 2020 Apr; 165(4):967-972. PubMed ID: 32060792
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Evaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samples.
    Chaturbhuj DN; Nirmalkar AP; Paranjape RS; Tripathy SP
    PLoS One; 2014; 9(2):e87441. PubMed ID: 24533056
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy.
    Bon I; Musumeci G; Pavoni M; Miserocchi A; Lo Presti A; Morini S; Caio G; Della Vittoria A; Gibellini D; Re MC
    New Microbiol; 2015 Apr; 38(2):289-92. PubMed ID: 25938756
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.
    Jaha B; Schenkel CD; Jörimann L; Huber M; Zaheri M; Neumann K; Leemann C; Calmy A; Cavassini M; Kouyos RD; Günthard HF; Metzner KJ;
    J Antimicrob Chemother; 2023 Sep; 78(9):2323-2334. PubMed ID: 37545164
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes.
    Sacks D; Ledwaba J; Morris L; Hunt GM
    J Clin Microbiol; 2017 Jan; 55(1):122-133. PubMed ID: 27795333
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection.
    Ntemgwa M; Gill MJ; Brenner BG; Moisi D; Wainberg MA
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):995-1002. PubMed ID: 18593348
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.
    Brumme CJ; Poon AFY
    Virus Res; 2017 Jul; 239():97-105. PubMed ID: 27993623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.